Peregrine Capital Management LLC Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Peregrine Capital Management LLC cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 99,346 shares of the medical equipment provider’s stock after selling 3,580 shares during the period. Peregrine Capital Management LLC owned approximately 0.14% of Lantheus worth $8,887,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LNTH. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the 3rd quarter valued at approximately $25,000. Signaturefd LLC raised its stake in shares of Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after buying an additional 134 shares in the last quarter. World Investment Advisors LLC purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $60,000. Finally, RiverPark Advisors LLC purchased a new position in shares of Lantheus during the 3rd quarter worth approximately $74,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $79.94 on Tuesday. The business’s fifty day moving average price is $91.17 and its two-hundred day moving average price is $97.53. The stock has a market cap of $5.56 billion, a PE ratio of 13.30 and a beta of 0.44. Lantheus Holdings, Inc. has a one year low of $56.06 and a one year high of $126.89.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price for the company. Truist Financial reissued a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $131.86.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by insiders.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.